Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB® technology.
Related news for (KNBIF)
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
- Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
- Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
- Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel